Cargando…
Novel Therapies in Glioblastoma
Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent impro...
Autores principales: | Perry, James, Okamoto, Masahiko, Guiou, Michael, Shirai, Katsuyuki, Errett, Allison, Chakravarti, Arnab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316989/ https://www.ncbi.nlm.nih.gov/pubmed/22530121 http://dx.doi.org/10.1155/2012/428565 |
Ejemplares similares
-
Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
por: Shirai, Katsuyuki, et al.
Publicado: (2012) -
Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation
por: Jacob, Naduparambil K, et al.
Publicado: (2012) -
A Multi-Institutional Experience in Pediatric High-Grade Glioma
por: Walston, Steve, et al.
Publicado: (2015) -
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
por: Becker, Aline P., et al.
Publicado: (2021) -
The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group
por: Chinnaiyan, Prakash, et al.
Publicado: (2008)